Boehringer Ingelheim, a Germany-based drugs company, is preparing to start an early-stage corporate venturing fund. At the NCET2 Global 1000 conference last month, Martin Heidecker (pictured), director of the Boehringer Ingelheim Venture Fund, said he was in mid-October relocating from Germany to Boston, US, to help “access early-stage deals from universities” as part of a separate…
Boehringer Ingelheim eyes universities
Oct 15, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024